Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21.913
Filtrar
1.
Zhonghua Yu Fang Yi Xue Za Zhi ; 55(4): 535-538, 2021 Apr 06.
Artículo en Chino | MEDLINE | ID: mdl-33858068

RESUMEN

From 2018 to 2019, 3 453 cases of high-risk population were screened by the Cancer Screening Program in Urban China (CanSPUC) in Hebei Province, with the age of (53.94±8.00). 147 and 686 cases of breast cancer positive and suspicious positive patients were found, with the positive rate and suspicious positive rate of 4.26% and 19.87% respectively. The suspicious positive rate of 45-49 years old age group was the highest (28.32%), and the positive rate of over 70 years old age group was the highest (7.32%). The positive detection rate of mammography combined with ultrasound was 5.16%, which was higher than that of ultrasound alone (2.46%) (χ²=30.28,P<0.001) or mammography alone (3.06%) (χ²=14.56,P<0.001).


Asunto(s)
Neoplasias de la Mama , Detección Precoz del Cáncer , Anciano , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/epidemiología , China/epidemiología , Humanos , Mamografía , Tamizaje Masivo , Persona de Mediana Edad , Población Urbana
2.
Artículo en Inglés | MEDLINE | ID: mdl-33800480

RESUMEN

This study analyzed national health data to assess convalescent hospital use among female cancer survivors according to age group. This retrospective study collected data from women recovering from breast, colon, and stomach cancer, based on health insurance claim data over 5 years (2013-2017), from the Korea Health Insurance Review and Assessment Service (KHIRA). Interestingly, the number of young and older women who were treated in convalescent hospitals increased every year. In addition, total medical expenses increased in both groups. The annual rate of convalescent hospitalization was higher in older women (8.29~16.39%) than in younger women (4.01~7.46%). The total yearly medical expenses of cancer survivors in convalescent hospitals increased in both age groups and all cancer types, and the range of increase rate was from 7.7% in young breast cancer survivors to 32.2% in young colon cancer survivors. Visit days and days of medication increased noticeably in young colon cancer survivors. Taken together, these data have confirmed the importance of developing standard guidelines for inpatient management in convalescent hospitals and the health management of women cancer survivors by cancer type. This includes establishing a health management system and medical policies.


Asunto(s)
Neoplasias de la Mama , Supervivientes de Cáncer , Anciano , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/terapia , Femenino , Hospitales de Convalecientes , Humanos , República de Corea/epidemiología , Estudios Retrospectivos , Sobrevivientes
3.
Artículo en Inglés | MEDLINE | ID: mdl-33804363

RESUMEN

BACKGROUND: Breast cancer is the most common cancer and the second leading cause of cancer-related death amongst American women. Endocrine-disrupting chemicals (EDCs), especially bisphenol A (BPA) and phthalates, have adverse effects on human health. However, the association of BPA and phthalates with breast cancer remains conflicting. This study aims to investigate the association of BPA and phthalates with breast cancer. METHODS: Correlative studies were identified by systematically searching three electronic databases, namely, PubMed, Web of Sciences, and Embase, up to November 2020. All data were analyzed using Stata 15.0. RESULTS: A total of nine studies, consisting of 7820 breast cancer cases and controls, were included. The urinary phthalate metabolite mono-benzyl phthalate (MBzP) and mono-2-isobutyl phthalate (MiBP) were negatively associated with breast cancer (OR = 0.73, 95% CI: 0.60-0.90; OR = 0.75, 95% CI: 0.58-0.98, respectively). However, the overall ORs for BPA, mono-ethyl phthalate (MEP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono-2-ethylhexyl phthalate (MEHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono-(3-carboxypropyl) phthalate (MCPP), and mono-butyl phthalate (MBP) were 0.85 (95% CI: 0.69-1.05), 0.96 (95% CI: 0.62-1.48), 1.12 (95% CI: 0.88-1.42), 1.13 (95% CI: 0.74-1.73), 1.01 (95% CI: 0.74-1.40), 0.74 (95% CI: 0.48-1.14), and 0.80 (95% CI: 0.55-1.15), respectively, suggesting no significant association. The sensitivity analysis indicated that the results were relatively stable. CONCLUSION: Phthalate metabolites MBzP and MiBP were passively associated with breast cancer, whereas no associations were found between BPA, MEP, MEHHP, MEHP, MEOHP, MCPP, and MBP and breast cancer. More high-quality case-control studies or persuasive cohort studies are urgently needed to draw the best conclusions.


Asunto(s)
Neoplasias de la Mama , Contaminantes Ambientales , Ácidos Ftálicos , Compuestos de Bencidrilo/toxicidad , Neoplasias de la Mama/inducido químicamente , Neoplasias de la Mama/epidemiología , Exposición a Riesgos Ambientales/análisis , Femenino , Humanos , Fenoles , Ácidos Ftálicos/toxicidad
4.
Artículo en Inglés | MEDLINE | ID: mdl-33806890

RESUMEN

BACKGROUND: For a decade, most population-based cancer screenings in China are performed by primary healthcare institutions. To assess the determinants of performance of primary healthcare institutions in population-based breast, cervical, and colorectal cancer screening in China. METHODS: A total of 262 primary healthcare institutions in Tianjin participated in a survey on cancer screening. The survey consisted of questions on screening tests, the number of staff members and training, the introduction of the screening programs to residents, the invitation of residents, and the number of performed screenings per year. Logistic regression models were used to analyze the determinants of performance of an institution to fulfil the target number of screenings. RESULTS: In 58% and 61% of the institutions between three and nine staff members were dedicated to breast and cervical cancer screening, respectively, whereas in 71% of the institutions ≥10 staff members were dedicated to colorectal cancer screening. On average 60% of institutions fulfilled the target number of breast and cervical cancer screenings, whereas 93% fulfilled the target number for colorectal cancer screening. The determinants of performance were rural districts for breast (OR = 5.16 (95%CI: 2.51-10.63)) and cervical (OR = 4.17 (95%CI: 2.14-8.11)) cancer screenings, and ≥3 staff members dedicated to cervical cancer screening (OR = 2.34 (95%CI: 1.09-5.01)). CONCLUSIONS: Primary healthcare institutions in China perform better in colorectal than in breast and cervical cancer screening, and institutions in rural districts perform better than institutions in urban districts. Increasing the number of staff members on breast and cervical cancer screening could improve the performance of population-based cancer screening.


Asunto(s)
Neoplasias de la Mama , Neoplasias Colorrectales , Neoplasias del Cuello Uterino , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/epidemiología , China , Neoplasias Colorrectales/diagnóstico , Detección Precoz del Cáncer , Femenino , Humanos , Tamizaje Masivo , Atención Primaria de Salud , Neoplasias del Cuello Uterino/diagnóstico
5.
Anticancer Res ; 41(4): 1903-1908, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33813395

RESUMEN

BACKGROUND/AIM: We employed a survey to the American Society of Plastic Surgeons (ASPS) to investigate the management of breast reconstruction across the US during the COVID-19 pandemic. PATIENTS AND METHODS: An electronic survey on breast reconstruction practice demographics, COVID-19-related restrictions on breast reconstruction, and pertinent dates of restrictions was employed. RESULTS: A total of 228 responses were obtained. Demographics were balanced for geography with most respondents located in either urban or suburban settings (91.2%). The majority proceeded with mastectomy/reconstruction as originally planned (39.0%), followed by hormonal/chemotherapy only (22.6%). The most common reconstructive option was tissue expander/implant-based reconstruction (47.7%). Most institutions implemented restrictions between March 11-20th (59%). Almost all respondents (91.8%) reported mandatory pre-operative SARS-Cov-2 testing once cases resumed. CONCLUSION: COVID-19 has forced the breast surgical team to adapt to new conditions to the detriment of women with breast cancer requiring reconstruction. Varying restrictions have limited access to breast reconstruction, carrying consequences yet to be determined.


Asunto(s)
/epidemiología , Mamoplastia/estadística & datos numéricos , Mastectomía/estadística & datos numéricos , Pandemias , Pautas de la Práctica en Medicina/estadística & datos numéricos , Implantes de Mama/estadística & datos numéricos , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Estudios Transversales , Femenino , Humanos , Control de Infecciones/normas , Cuarentena , Cirujanos/estadística & datos numéricos , Encuestas y Cuestionarios , Dispositivos de Expansión Tisular/estadística & datos numéricos , Estados Unidos/epidemiología
6.
Anticancer Res ; 41(4): 2193-2195, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33813433

RESUMEN

BACKGROUND/AIM: Since January 2020, coronavirus disease (COVID-19) cases have been confirmed in Japan, and the number of patients with COVID-19 has been increasing. Two emergency declarations have been made previously and one is currently in effect. Based on our experience of a situation that could affect cancer treatment, this study retrospectively examined the correlation between perioperative anticancer therapy and COVID-19 incidence in patients with breast cancer. PATIENTS AND METHODS: Patients who underwent perioperative anticancer therapy for breast cancer at our hospital from February 2020 to February 2021 were included in this study. The presence or absence of COVID-19, timing of anticancer drug initiation, and clinical data were collected. RESULTS: No cases of COVID-19 were diagnosed in patients receiving perioperative anticancer therapy at our hospital. CONCLUSION: Regimen modification, active use of supportive care, and patient lifestyle were factors reducing the incidence of COVID-19.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Neoplasias de la Mama , Atención Perioperativa/métodos , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante/estadística & datos numéricos , Terapia Combinada , Femenino , Humanos , Huésped Inmunocomprometido , Incidencia , Japón/epidemiología , Persona de Mediana Edad , Terapia Neoadyuvante/estadística & datos numéricos , Atención Perioperativa/efectos adversos , Atención Perioperativa/estadística & datos numéricos , Estudios Retrospectivos , Factores de Riesgo , /fisiología
7.
Zhonghua Zhong Liu Za Zhi ; 43(4): 357-382, 2021 Apr 23.
Artículo en Chino | MEDLINE | ID: mdl-33902200

RESUMEN

Breast cancer is the commonest malignant tumor among Chinese females, ranking first in terms of incidence of female cancers. Commissioned by the Disease Prevention and Control Bureau of National Health Commission of the People's Republic of China, the National Cancer Center formulated the Guideline for Screening and Early Diagnosis and Treatment of Female Breast Cancer in China according to WHO Handbook for Guideline Development. The methods on Cochrane China were referred to for the formulation of the system evaluation procedures. The GRADE methods for assessment, formulation and evaluation were adopted for the classification of evidence quality and recommendation strength, and the items were reported according to Reporting Items for Practice Guidelines in Healthcare. Based on the results of evaluation, the guideline gives evidence-based recommendations for the appropriate population and technical procedures for breast cancer screening and early diagnosis and treatment after comprehensive consideration of China's national conditions, the advantages and disadvantages of the evidence, the quality of the evidence, the economic cost of screening, the feedback of multidisciplinary clinical research respondents, and in-person expert consensus. It is aimed at regulating the practices of female breast cancer screening and early diagnosis and treatment and enhancing the effectiveness of the prevention and control of female breast cancer in China.


Asunto(s)
Neoplasias de la Mama , Beijing , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/epidemiología , China/epidemiología , Detección Precoz del Cáncer , Femenino , Humanos , Tamizaje Masivo
9.
J Hematol Oncol ; 14(1): 64, 2021 04 17.
Artículo en Inglés | MEDLINE | ID: mdl-33865430

RESUMEN

BACKGROUND: The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt and increased the burden on health care services, necessitating the introduction of specific breast cancer treatment recommendations from week 12 of 2020. We aimed to investigate the impact of COVID-19 on the diagnosis, stage and initial treatment of breast cancer. METHODS: Women included in the Netherlands Cancer Registry and diagnosed during four periods in weeks 2-17 of 2020 were compared with reference data from 2018/2019 (averaged). Weekly incidence was calculated by age group and tumor stage. The number of women receiving initial treatment within 3 months of diagnosis was calculated by period, initial treatment, age, and stage. Initial treatment, stratified by tumor behavior (ductal carcinoma in situ [DCIS] or invasive), was analyzed by logistic regression and adjusted for age, socioeconomic status, stage, subtype, and region. Factors influencing time to treatment were analyzed by Cox regression. RESULTS: Incidence declined across all age groups and tumor stages (except stage IV) from 2018/2019 to 2020, particularly for DCIS and stage I disease (p < 0.05). DCIS was less likely to be treated within 3 months (odds ratio [OR]wks2-8: 2.04, ORwks9-11: 2.18). Invasive tumors were less likely to be treated initially by mastectomy with immediate reconstruction (ORwks12-13: 0.52) or by breast conserving surgery (ORwks14-17: 0.75). Chemotherapy was less likely for tumors diagnosed in the beginning of the study period (ORwks9-11: 0.59, ORwks12-13: 0.66), but more likely for those diagnosed at the end (ORwks14-17: 1.31). Primary hormonal treatment was more common (ORwks2-8: 1.23, ORwks9-11: 1.92, ORwks12-13: 3.01). Only women diagnosed in weeks 2-8 of 2020 experienced treatment delays. CONCLUSION: The incidence of breast cancer fell in early 2020, and treatment approaches adapted rapidly. Clarification is needed on how this has affected stage migration and outcomes.


Asunto(s)
Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/terapia , Adulto , Anciano , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/patología , Manejo de la Enfermedad , Femenino , Humanos , Incidencia , Tamizaje Masivo , Persona de Mediana Edad , Estadificación de Neoplasias , Países Bajos/epidemiología
10.
Zhonghua Zhong Liu Za Zhi ; 43(4): 497-503, 2021 Apr 23.
Artículo en Chino | MEDLINE | ID: mdl-33902214

RESUMEN

Objective: To evaluate the effectiveness and quality of ultrasound-based (BUS) process optimization in breast cancer screening. Methods: The program collected the first to fourth quarterly breast cancer screening statistic data and case report data from 30 provinces, autonomous regions and municipalities in 2015 by the online report system of national key service program of women and children's public health. The call rate, mammography (MG) subsequent screen rate, biopsy rate, detection rate, early diagnosis rate, carcinoma in situ rate, missing detection rate, false positive rate and positive predictive value (PPV) of breast cancer were calculated. Results: A total of 1 501 753 rural women attended the BUS process optimization screening. The nationwide recall rate was 3.01%(45 156/1 501 753), and in the eastern and central area were 3.41%(17 173/503 130) and 3.56%(14 499/407 739), respectively, higher than 2.28% (13 484/590 884) of western area (P<0.05). The nationwide MG subsequent screen rate was 2.78%(41 694/1 501 753), and in the eastern and central area were 3.19%(16 036/503 130) and 3.29% (13 421/407 739), respectively, higher than 2.07%(12 237/590 884) of western area (P<0.05). The nationwide biopsy rate was 0.23%(3 462/1 501 753), and in the central area were 0.26%(1 078/407 739), respectively, higher than 0.21%(1 247/590 884) of western area and 0.23% (1 137/503 130) of eastern area (P<0.05). The nationwide biopsy PPV was 37.00%(1 281/3 462). The biopsy PPV of eastern area was (34.30%, 390/1 137), lower than 39.33% (424/1 078) of central area (P<0.05). A total of 1 281 cases of breast cancer were detected, the detection rate was 0.85‰(1 281/1 501 753), and the detection rates of central area was 1.04‰ (424/407 739), higher than 0.79‰(467/590 884) of western area and 0.78‰(390/503 130) of eastern area (P<0.05). The BUS initiate screening positive rate from detected breast cancer cases was 96.96%(1 242/1 281), the MG subsequent screening positive rate was 2.42%(31/1 281). The nationwide early diagnosis rate was 85.25%(1 092/1 281), and in the eastern and central areas were 87.95%(343/390) and 88.21%(374/424), higher than 80.30%(375/467) of western area (P<0.05). The screening rate of on or above stage Ⅱ breast cancer in eastern area was 55.64%(217/390), lower than 64.62%(374/424) of central area and 62.31%(291/467) of western area. The missing detection rate was 0.62%(8/1 281) and false positive rate was 1.20%(17 528/1 464 149). Conclusions: The BUS process optimization of breast cancer screening scheme is reasonable and applicable to China rural women. The effectiveness and quality of eastern area are superior to those of central and western area.


Asunto(s)
Neoplasias de la Mama , Detección Precoz del Cáncer , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/epidemiología , Niño , China/epidemiología , Femenino , Humanos , Mamografía , Tamizaje Masivo
11.
Mayo Clin Proc ; 96(4): 1033-1040, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33814072

RESUMEN

Breast cancer remains the most common cancer in women in the United States. For certain women at high risk for breast cancer, endocrine therapy (ET) can greatly decrease the risk. Tools such as the Breast Cancer Risk Assessment Tool (or Gail Model) and the International Breast Cancer Intervention Study risk calculator are available to help identify women at increased risk for breast cancer. Physician awareness of family history, reproductive and lifestyle factors, dense breast tissue, and history of benign proliferative breast disease are important when identifying high-risk women. The updated US Preventive Services Task Force and American Society of Clinical Oncology guidelines encourage primary care providers to identify at-risk women and offer risk-reducing medications. Among the various ETs, which include tamoxifen, raloxifene, anastrozole, and exemestane, tamoxifen is the only one available for premenopausal women aged 35 years and older. A shared decision-making process should be used to increase the usage of ET and must be individualized. This individualized approach must account for each woman's medical history and weigh the benefits and risks of ET in combination with the personal values of the patient.


Asunto(s)
Anastrozol/administración & dosificación , Neoplasias de la Mama/prevención & control , Antagonistas de Estrógenos/administración & dosificación , Personal de Salud/educación , Medicina Preventiva/educación , Clorhidrato de Raloxifeno/administración & dosificación , Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación , Tamoxifeno/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/epidemiología , Curriculum , Toma de Decisiones Conjunta , Educación Médica Continua , Femenino , Humanos , Masculino , Persona de Mediana Edad , Medicina Preventiva/métodos , Medición de Riesgo , Factores de Riesgo , Estados Unidos/epidemiología
12.
Artículo en Inglés | MEDLINE | ID: mdl-33671649

RESUMEN

OBJECTIVES: To assess shared decision-making (SDM) knowledge, attitude and application among health professionals involved in breast cancer (BC) treatment. MATERIALS AND METHODS: A cross-sectional study based on an online questionnaire, sent by several professional societies to health professionals involved in BC management. There were 26 questions which combined demographic and professional data with some items measured on a Likert-type scale. RESULTS: The participation (459/541; 84.84%) and completion (443/459; 96.51%) rates were high. Participants strongly agreed or agreed in 69.57% (16/23) of their responses. The majority stated that they knew of SDM (mean 4.43 (4.36-4.55)) and were in favour of its implementation (mean 4.58 (4.51-4.64)). They highlighted that SDM practice was not adequate due to lack of resources (3.46 (3.37-3.55)) and agreed on policies that improved its implementation (3.96 (3.88-4.04)). The main advantage of SDM for participants was patient satisfaction (38%), and the main disadvantage was the patients' paucity of knowledge to understand their disease (24%). The main obstacle indicated was the lack of time and resources (40%). CONCLUSIONS: New policies must be designed for adequate training of professionals in integrating SDM in clinical practice, preparing them to use SDM with adequate resources and time provided.


Asunto(s)
Neoplasias de la Mama , Toma de Decisiones Conjunta , Neoplasias de la Mama/epidemiología , Estudios Transversales , Toma de Decisiones , Humanos , Participación del Paciente , Encuestas y Cuestionarios
13.
Artículo en Inglés | MEDLINE | ID: mdl-33671879

RESUMEN

Stress is a common belief among breast cancer patients and the public to explain variation in breast cancer incidence. Epidemiological studies interrogating the relationship between stress and cancer have reported mixed results. The impact of the topic and the lack of consensus has sparked this review of the literature to investigate gaps in knowledge and identify areas of research. We first present a brief summary of the biopsychosocial model generally used to conduct research on stress. We then divide the overview of the literature into areas of research focus. These include the role of distressing life events in breast cancer incidence, the role of adverse childhood events in later breast cancer incidence, the importance of race and socioeconomic status (SES) as social determinants of breast cancer incidence, and the specific role of chronic stress in relation to breast cancer. For each topic, we discuss the potential of stress as a risk factor and possible intervention strategies that could reduce the effects of stress. We then identify further research questions to be probed to fill the gaps in knowledge. We conclude with a discussion of future research directions for stress research as it relates to breast cancer incidence.


Asunto(s)
Neoplasias de la Mama , Neoplasias de la Mama/epidemiología , Niño , Humanos , Incidencia , Factores de Riesgo , Clase Social
14.
Endocr Pract ; 27(4): 298-305, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33779560

RESUMEN

OBJECTIVES: The results of studies investigating the relationship between breast cancer and hypothyroidism vary greatly from study to study. In this study, we analyzed a large and reliable, population-based database to gain a better understanding of the correlation. METHODS: This retrospective cohort study analyzed patients with hypothyroidism between January 1, 2000 and December 31, 2012 (hypothyroidism cohort) from the Longitudinal Health Insurance Database 2000 in Taiwan. For each woman with hypothyroidism, 1 woman without a history of breast cancer was randomly selected from the Longitudinal Health Insurance Database 2000 and frequency matched (1:4) with women without hypothyroidism by age and index year of hypothyroidism. The study outcome was the diagnosis of breast cancer during a 12-year follow-up period. RESULTS: In this study, 6665 women with hypothyroidism and 26 660 women without hypothyroidism were identified. The hypothyroidism cohort had a significantly higher risk of breast cancer than the nonhypothyroidism cohort (adjusted hazard ratio [aHR] 1.69 [95% CI, 1.15-2.49]; P = .01), especially in the group aged 40 to 64 years (aHR 2.07 [95% CI, 1.32-3.23]; P = .01). Women in the hypothyroidism cohort taking levothyroxine for a duration ˃588 days showed a significantly decreased risk of breast cancer (aHR 0.37 [95% CI, 0.19-0.71]; P = .003). CONCLUSION: Women with hypothyroidism are at a higher risk of breast cancer than those without hypothyroidism. Levothyroxine may reduce the risk of breast cancer in a woman with hypothyroidism.


Asunto(s)
Neoplasias de la Mama , Hipotiroidismo , Adulto , Neoplasias de la Mama/epidemiología , Estudios de Cohortes , Femenino , Humanos , Hipotiroidismo/complicaciones , Hipotiroidismo/epidemiología , Incidencia , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Factores de Riesgo , Taiwán/epidemiología
15.
Environ Pollut ; 277: 116848, 2021 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-33714786

RESUMEN

Breast cancer is the most commonly diagnosed female cancer and the second leading cause of death in women in the US, including Hawaii. Accumulating evidence suggests that aminomethylphosphonic acid (AMPA), the primary metabolite of the herbicide glyphosate-a probable human carcinogen, may itself be carcinogenic. However, the relationship between urinary AMPA excretion and breast cancer risk in women is unknown. In this pilot study, we investigated the association between pre-diagnostic urinary AMPA excretion and breast cancer risk in a case-control study of 250 predominantly postmenopausal women: 124 cases and 126 healthy controls (individually matched on age, race/ethnicity, urine type, date of urine collection, and fasting status) nested within the Hawaii biospecimen subcohort of the Multiethnic Cohort. AMPA was detected in 90% of cases and 84% of controls. The geometric mean of urinary AMPA excretion was nearly 38% higher among cases vs. controls (0.087 vs 0.063 ng AMPA/mg creatinine) after adjusting for race/ethnicity, age and BMI. A 4.5-fold higher risk of developing breast cancer in the highest vs. lowest quintile of AMPA excretion was observed (ORQ5 vs. Q1: 4.49; 95% CI: 1.46-13.77; ptrend = 0.029). To our knowledge, this is the first study to prospectively examine associations between urinary AMPA excretion and breast cancer risk. Our preliminary findings suggest that AMPA exposure may be associated with increased breast cancer risk; however, these results require confirmation in a larger population to increase study power and permit careful examinations of race/ethnicity differences.


Asunto(s)
Neoplasias de la Mama , Herbicidas , Neoplasias de la Mama/epidemiología , Estudios de Casos y Controles , Estudios de Cohortes , Femenino , Glicina/análogos & derivados , Hawaii/epidemiología , Herbicidas/análisis , Humanos , Organofosfonatos , Proyectos Piloto
16.
Zhonghua Yu Fang Yi Xue Za Zhi ; 55(3): 359-364, 2021 Mar 06.
Artículo en Chino | MEDLINE | ID: mdl-33730828

RESUMEN

Objective: To investigate the relationship between metabolic syndrome (MS) and the risk of breast cancer in Chinese females. Methods: From May 2006 to December 2015, based on the Kailuan Women's Dynamic Cohort,a total of 25 618 female employees and retirees of the Kailuan Group were included and followed. Questionnaire surveys, physical measurements and laboratory tests were used to collect baseline sociodemographic characteristics, height, weight, blood glucose, blood lipids, blood pressure, tumor incidence and outcome information. Cox proportional hazards regression models were used to analyze the relationship between MS and its components (body mass index, blood pressure, blood glucose and blood lipid) and the risk of breast cancer in females. Results: The age of 25 618 women was (47.65±12.02) years old and median follow-up time was 8.78 years; 235 new cases of breast cancer were detected, and the incidence density was 113.19/100 000 person-years. After adjusting for age, education, income, smoking status, drinking status and other factors, people who were overweight or obese had a higher risk of breast cancer, with HR (95%CI) about 1.47 (1.12-1.93), than those with normal body mass index. Compared with those without MS abnormal components, women with two MS abnormal components had an increased risk of breast cancer (HR=1.70, 95%CI: 1.16-2.50). With the increase of the number of MS abnormal components, the risk of breast cancer increased gradually (Ptrend value<0.05). Conclusion: Overweight/obesity and the number of abnormal components of MS can increase the risk of breast cancer in women.


Asunto(s)
Neoplasias de la Mama , Síndrome Metabólico , Adulto , Índice de Masa Corporal , Neoplasias de la Mama/epidemiología , China/epidemiología , Femenino , Humanos , Incidencia , Síndrome Metabólico/epidemiología , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Factores de Riesgo
17.
Medicine (Baltimore) ; 100(9): e25024, 2021 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-33655973

RESUMEN

ABSTRACT: An irrational belief is the direct cause of negative emotions and behavioral disorders in patients with breast cancer. Thus, this article examines these patients' irrational beliefs, which helps improve the emotions and behavioral disorders of breast cancer patients. Chinese breast cancer patients have unique irrational beliefs due to the influence of Chinese traditional culture. To understand the irrational beliefs surrounding breast cancer diagnosis in young Chinese patients, we conducted an interpretative phenomenological study.Semi-structured interviews were conducted in young Chinese breast cancer patients. According to Colaizzi method modified by Edward and Welsh, transcribed interviews were analyzed to understand patients' irrational beliefs. Based on the theoretical framework, this study adopted interpretative phenomenology. Interpretive description was used to construct participants' experiences of irrational beliefs. Thematic sufficiency was confirmed after 17 interviews.Owing to the lack of knowledge about breast cancer, all participants were more susceptible to traditional Chinese culture, empiric theory, family reassurance, and healthcare providers' behaviors, leading to patients' irrational beliefs, negative emotions, and behavioral disorders.This research confirms that irrational beliefs in young Chinese breast cancer patients are profoundly influenced by traditional Chinese culture. Chinese healthcare providers can use this information to provide targeted nursing, supportive services, and research, and help women identify their beliefs and understand how these beliefs affect their health.


Asunto(s)
Neoplasias de la Mama/diagnóstico , Cultura , Emociones/fisiología , Encuestas y Cuestionarios , Adulto , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/psicología , China/epidemiología , Femenino , Humanos , Morbilidad/tendencias
18.
BMC Cancer ; 21(1): 229, 2021 Mar 06.
Artículo en Inglés | MEDLINE | ID: mdl-33676446

RESUMEN

BACKGROUND: A recent study found an influence of organized mammography screening programmes (MSPs) on geographical and temporal variation of mastectomy rates. We aimed to quantify the effect on the example of one of the cantonal programmes in Switzerland. METHODS: We used incidence data for the years 2010-2017 from the cancer registry of Eastern Switzerland. We included women with invasive-non-metastatic breast cancer (BC) in the screening age group 50-69-year-olds in the canton of St.Gallen. We compared mastectomy rates among cancer patients detected through the organised screening programme (MSP) vs. otherwise detected by stage. RESULTS: MSP-detected patients in St.Gallen presented with lower stages. 95% of MSP-detected had stages I-II vs 76% of Non-MSP-detected. Within all non-metastatic stage, tumour size and nodal status groups, MSP-detected patients had lower mastectomy rates, overall 10% vs 24% in 50-69-year-old non-participants. Their odds of receiving a mastectomy are about half of the Non-MSP-detected (OR = 0.48, p = 0.002). CONCLUSIONS: Our study showed that MSPs have a positive effect on lowering mastectomy rates. Screening participants are significantly less likely to receive a mastectomy compared to non-participants, which must be attributed to additional factors than just lower stages. Lower mastectomy rates lead to a higher quality of life for many patients.


Asunto(s)
Neoplasias de la Mama/cirugía , Detección Precoz del Cáncer/estadística & datos numéricos , Mamografía/estadística & datos numéricos , Tamizaje Masivo/organización & administración , Mastectomía/estadística & datos numéricos , Anciano , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/epidemiología , Femenino , Geografía , Humanos , Incidencia , Tamizaje Masivo/estadística & datos numéricos , Mastectomía/efectos adversos , Persona de Mediana Edad , Estadificación de Neoplasias , Evaluación de Programas y Proyectos de Salud , Calidad de Vida , Sistema de Registros/estadística & datos numéricos , Suiza/epidemiología
20.
Nursing ; 51(3): 58-62, 2021 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-33674538

RESUMEN

ABSTRACT: Lesbian and bisexual women may be at an increased risk for gynecologic infections and breast cancer due to a higher prevalence of factors such as obesity, smoking, and lower pregnancy rates. This article discusses the role of healthcare professionals in preventive screening for breast and gynecologic cancers and promoting healthy living in these patients by avoiding smoking, maintaining an ideal body weight, and limiting alcohol consumption.


Asunto(s)
Bisexualidad , Neoplasias de la Mama/enfermería , Detección Precoz del Cáncer/enfermería , Neoplasias de los Genitales Femeninos/enfermería , Homosexualidad Femenina , Neoplasias de la Mama/epidemiología , Femenino , Neoplasias de los Genitales Femeninos/epidemiología , Humanos , Medición de Riesgo , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...